Qiagen N.V.

  • ISIN: NL0012169213
  • Land: The Netherlands

Nachricht vom 14.11.2017 | 18:05

QIAGEN N.V.: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution


14.11.2017 / 18:05
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The AFM (the Netherlands Authority For the Financial Markets) has informed us on November 10, 2017 that a notification related to our institution has been released by the AFM.

The following notification has been disclosed in the relevant register on the AFM website:

Date of transaction: 08 nov 2017
Person obliged to notify: Massachusetts Financial Services Company
Issuing institution: QIAGEN N.V.
Registration Chamber of Commerce: 12036979
Place of residence: VENLO

Distribution in numbers

Type of share Number of shares Number of voting rights Capital interest Voting rights Manner of disposal Settlement Explanation
Ordinary share 3.374.131,00 4.760.400,00 Real Real Directly  
Ordinary share 1.104.976,00 2.386.183,00 Real Real Indirectly
(MFS Investment Management Canada Ltd; MFS
Heritage Trust Company; MFS International
Australia Pty. Ltd; MFS Investment Management
K.K.; MFS Investment Management; MFS
Institutional Advisors, Inc; MFS International
(U.K.) Ltd; MFS International Singapore P)

Distribution in percentages

Type Total holding Directly real Directly potential Indirectly real Indirectly potential
Capital interest 1,94 % 1,46 % 0,00 % 0,48 % 0,00 %
Voting rights 3,10 % 2,06 % 0,00 % 1,03 % 0,00 %

QIAGEN N.V. is not responsible for the accuracy and correctness of the notification above. The content has been taken from the relevant register of the AFM:

14.11.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

News im Fokus

Commerzbank baut Privatkundenberatung zu ETFs aus

19. Januar 2018, 14:10

Aktuelle Research-Studie

Sanochemia Pharmazeutika AG

Original-Research: Sanochemia Pharmazeutika AG (von Sphene Capital GmbH): Buy

19. Januar 2018